The FDA on November 14, 2022, granted accelerated approval to ELAHEREĀ® (Mirvetuximab soravtansine-gynx) for adult patients with Folate Receptor alpha (FRĪ±) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. ELAHEREĀ® is a Folate Receptor alpha directed antibody and microtubule inhibitor conjugate. Patients are selected for therapy based on an FDA-approved test. ELAHEREĀ® is a product of ImmunoGen, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
